Investigate the effect of induction MEPFL chemotherapy followed by concurrent chemoradiotherapy (CCRT) on the disease control and survival in treatment of patients with advanced NPC.
Rationale of induction chemotherapy: Distant metastasis is the major cause of treatment failure and deaths in patients with loco-regionally advanced NPC. Concurrent chemoradiotherapy may prolong survivals for patients with advanced NPC, but it is still flawed by high incidence of distant metastasis. Induction chemotherapy with MEPFL has been shown to reduce the incidence of distant metastasis in a Phase II study. Induction chemotherapy plus concurrent chemoradiotherapy may improve the survival of patients with advanced NPC. Objectives: Investigate the effect of induction MEPFL chemotherapy followed by concurrent chemoradiotherapy (CCRT) on the disease control and survival in treatment of patients with advanced NPC. Study design: This is a randomized, multi-center Phase III study. Patients will be randomized to CCRT with or without the MEPFL induction chemotherapy. Type and number of patients: Patients with stage IVA (T4) and/or IVB (N3) but without distant metastasis will be enrolled. A total of up to 480 patients will be randomized to detect an improvement of median overall survival from 5.8 to 8.7 years, with an a=0.05 and power of 0.8 using a two-sided logrank test with one interim analysis. Treatment schedule: Induction chemotherapy and CCRT: Arm A: Weekly cisplatin concurrently with radiotherapy Arm B: Induction MEPFL three cycles followed with weekly cisplatin concurrently with radiotherapy. Study endpoints: The primary endpoint is the disease-free survival that will be calculated as the duration between the date of randomization and the date of recurrence of NPC at any site including persistent disease after +induction chemotherapy/CCRT, or death from any cause (failed), or the date of withdrawal (last contact date, censored), or the scheduled data analysis date (censored).( revised 8/27/2004)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
480
Radiation with weekly Cisplatin
Induction C/T + CCRT
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan
China Medical University Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Chang-Gung Memorial Hospital(Lin-Kou),
Taoyuan District, Taiwan
The primary endpoint is the disease-free survival.
follow up for 2 years after off study treatment
Time frame: 10 years
Secondary endpoints include overall survival and tumor response rate.
follow up for 2 years after off study treatment
Time frame: 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.